title: Long-term disease control of a pancreatic neuroendocrine tumor with lanreotide autogel(®): a case report.
abstract: The CLARINET study (ClinicalTrials.gov: NCT00353496) showed that somatostatin analogs are able to stabilize tumor growth in patients with intestinal and pancreatic neuroendocrine tumors (NETs). Here, we present a case of NET originating from the pancreatic tail that was treated with lanreotide Autogel(®). A 60-year-old patient underwent resection of a pancreatic NET with splenectomy and distal pancreatectomy. Four months after surgery, there was an increase in chromogranin A levels, along with a hypercaptating lesion of approximately 3.5 cm at the residual part of the pancreatic corpus. Treatment with 30 mg monthly-administered octreotide long-acting release (LAR) was initiated. After 3 months of treatment, a control CT scan revealed diffuse metastases in the liver, although the patient presented no symptoms and liver tests were normal. Due to difficulties with the administration of octreotide LAR, treatment was switched to lanreotide Autogel(®) 120 mg, administered as monthly deep-subcutaneous injections. Progression-free survival, as shown by 3-monthly CT scans, was obtained for 2 years without the need to increase the lanreotide Autogel(®) dose, and the patient reported no side effects. After these 2 years, deterioration of the patient's clinical status and weight loss were observed, along with increased size of the liver lesions and appearance of peritoneal metastases. Chemotherapy treatment with cisplatinum-etoposide was initiated, while the lanreotide Autogel(®) injections were continued. After three chemotherapy cycles, a rapid decline in the patient's quality of life was noted, and she requested discontinuation of the chemotherapy and lanreotide injections. One month later, the patient died due to clinical progressive disease.
authors.affiliation: AZ Nikolaas, Sint-Niklaas, Belgium.
authors.forename: Willem
authors.initials: W
authors.lastname: Lybaert
authors.affiliation: AZ Nikolaas, Sint-Niklaas, Belgium.
authors.forename: Erik
authors.initials: E
authors.lastname: Van Hul
authors.affiliation: AZ Nikolaas, Sint-Niklaas, Belgium.
authors.forename: Heidi
authors.initials: H
authors.lastname: Woestenborghs
keywords: Lanreotide Autogel®; Pancreatic neuroendocrine tumor; Somatostatin analog